Navigation Links
HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:4/25/2011

SAN DIEGO, April 25, 2011 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study, which is being conducted by investigators in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon, is expected to enroll approximately 50 patients. The primary objective is safety and tolerability of HQK-1001. There are several secondary objectives including an increase in fetal hemoglobin production. HemaQuest expects interim results from the study in late 2011 and final results in the first quarter of 2012.

"Based on the promising results from our prior Phase 2 clinical studies, we are excited to initiate this clinical study testing higher dose levels and longer duration of therapy to more fully characterize the therapeutic potential of HQK-1001 in sickle cell disease," said HemaQuest Chief Medical Officer Richard G. Ghalie, MD. "This is an important next step toward potentially making HQK-1001 available as a treatment for this devastating disease in underserved populations around the world."

ABOUT HQK-1001 HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia.  Increased fetal hemoglobin production in red blood cells has been shown to reduce the frequency of pain crises and hospitalizations  of patients with sickle cell disease  HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile a
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
2. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
3. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Advanced Wound Dressings - ... Advanced dressings have steadily replaced traditional bandages and ... of wound indications, such as trauma wounds, burns, ... and physical protection become increasingly critical in wound ... standard therapy. This report focuses on nine ...
(Date:9/2/2015)... PHILADELPHIA, Pa. , Sept. 2, 2015 /PRNewswire/ ... Substantially increases, diversifies revenue base with highly profitable ... products , Near-term growth potential with 11 ... five include Paragraph IV certifications  , Provides ... product candidates in development, including eight controlled substances ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ... Drug Delivery (London, UK - November 19-20, 2015)" ... Delivery meeting will cover industry case studies, regulatory updates, ... Co-Chairmen are Dr Steven Nichols , OINP Specialist ... Companies participating include: ...
Breaking Medicine Technology:Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
... SeqWright Inc., an international leader in the field ... Hologic,s (formerly Third Wave Technologies) successful clinical trials of ... tests. SeqWright provided FDA submission quality DNA sequencing ... two Hologic HPV diagnostic tests; Cervista HPV ...
... Application to Expand the NUVIGIL(R) Label , FRAZER, Pa., ... CEPH ) today announced positive results from a ... as a treatment for excessive sleepiness associated with jet ... file a supplemental New Drug Application with the U.S. ...
Cached Medicine Technology:SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Fashion designer ... very beginning of the most recent episode of the hit ABC series “Extreme ... fit the image of her industry. She provided herself with the motivation to transform ...
(Date:9/2/2015)... ... September 03, 2015 , ... ... University Bloomberg School of Public Health and an internationally recognized scholar on obesity ... for 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Symposium (WFS), cosponsored by the Military Officers Association of America (MOAA) and ... "Our Nation's Military: Caring For Our Own,” expert panelists will lead interactive ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Telehealth represents a ... Corp., contracted to handle the telehealth services of more than 12 Blues plan clients. ... Blue Shield Plans takes a look this growing trend, interviewing executives at Capital Blue ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... In “Failure ... by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong struggle ... the author acknowledged that she had always seen herself as someone who would lose ...
Breaking Medicine News(10 mins):Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2
... issued a special Briefing on the employer and Medicare- ... care reform, detailing provisions of the legislation approved on ... http://hr.cch.com/pdf/SpecialReport_HealthcareReform_11-09.pdf . , The Affordable ... the House of Representatives with significant changes to the ...
... Campaign to Pass Bill Includes New Radio Ads Airing Today ... of a bill to repeal the broken Medicare physician payment ... a new dimension to its Medicare campaign today with radio ... to the ads, the AMA is activating its nationwide grassroots ...
... Minn., Nov. 13 Here are highlights from the November ... cite this publication as often as you wish. Reprinting is ... attribution is required. Include the following ... www.HealthLetter.MayoClinic.com or ...
... FREMONT, Calif., Nov. 13 Microfluidic Systems, a privately-held ... entitled "Microfluidic Valve Mechanism". This patent covers ... a diaphragm membrane into a rigid body of a ... of the cartridge, and as a valve mechanism for ...
... of safety and lawfulness of selling such beverages , FRIDAY, ... that they plan to look into the safety and legality ... , Prompted by a request from several states, attorneys general, ... of such drinks 30 days to show the agency why ...
... and offering little gap coverage , FRIDAY, Nov. ... Medicare prescription drugs plans (PDP) could encounter significant changes ... premiums will rise 11 percent to $38.94, on average, ... Kaiser Family Foundation. That,s up 50 percent from 2006, ...
Cached Medicine News:Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 2Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 3Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 4Health News:Employer, Medicare Provisions of House Health Care Reform Detailed in New CCH Briefing 5Health News:AMA Calls on Congress to Pass H.R. 3961, Access to Care for Seniors and Military Families at Stake 2Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 2Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 3Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 4Health News:November 2009 Mayo Clinic Health Letter Highlights Self-Care Tips for Hemorrhoids, Interactive Video Games Improve Health and Heart Failure Treatments 5Health News:Microfluidic Systems (MFSI) Receives Patent for Microfluidic Valve Mechanism 2Health News:FDA Questions Safety of Caffeinated Alcoholic Drinks 2Health News:Medicare Part D: What to Expect This Open Enrollment Period 2Health News:Medicare Part D: What to Expect This Open Enrollment Period 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: